IMCY-0098
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| UNII | |
| Chemical and physical data | |
| Formula | C95H157N29O28S2 |
| Molar mass | 2217.60 g·mol−1 |
IMCY-0098 is a peptide immunotherapy based on proinsulin and developed by Imcyse to reduce the progression of type 1 diabetes.[1][2]
References
[edit]- ^ Van Rampelbergh, Jean; Achenbach, Peter; Leslie, Richard David; Ali, Mohammad Alhadj; Dayan, Colin; Keymeulen, Bart; Owen, Katharine R.; Kindermans, Martin; Parmentier, Frédéric; Carlier, Vincent; Ahangarani, Roxana R.; Gebruers, Evelien; Bovy, Nicolas; Vanderelst, Luc; Van Mechelen, Marcelle; Vandepapelière, Pierre; Boitard, Christian (24 May 2023). "First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes". BMC Medicine. 21 (1): 190. doi:10.1186/s12916-023-02900-z. ISSN 1741-7015. PMC 10210318. PMID 37226224.
- ^ Atkinson, Mark A; Roep, Bart O; Posgai, Amanda; Wheeler, Daniel C S; Peakman, Mark (January 2019). "The challenge of modulating β-cell autoimmunity in type 1 diabetes". The Lancet Diabetes & Endocrinology. 7 (1): 52–64. doi:10.1016/S2213-8587(18)30112-8. PMC 7322790. PMID 30528099.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |